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ABSTRACT
The number of older adults living with cancer is
increasing. There is a clear lack of representa-
tion of older adults in clinical trials, including
cancer trials. Reasons for this are multifactorial
and complex and include protocol, patient and
sponsor factors. Potential solutions to overcome
issues with trial design include varied methods
of recruitment with flexible inclusion criteria.
Possible alternatives to randomised trials
include prospective cohort studies, pragmatic
trials and the use of national population-based
data sets. Patient factors may be addressed by
integration of geriatric assessment, so patients
can be randomised or treated based on their
individual needs. Additionally, standard proto-
cols for including older adults with cognitive
impairment should be developed, rather than
automatic exclusion. Increased effort is needed
from sponsors and governing health care bodies
to make recruitment of older adults to clinical
trials standard.
Keywords: Cancer trials; Clinical trials;
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Key Summary Points
Older adults remain under-represented in
cancer clinical trials, despite a willingness
to participate in research.
Alternative study designs may be
considered to address the fact that older
adults potentially have different
treatment goals compared to the younger
population.
When securing trial funding, special
consideration should be made to fund
additional resources specific to older
adults including integration of geriatric
assessment and assistance with transport
and communication.
Patients with cognitive impairment
should not be automatically excluded
from inclusion in trials.
Trial sponsors have a duty to raise
awareness and include older adults as
appropriate.
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INTRODUCTION
Our population is ageing; virtually every coun-
try in the world is experiencing growth in the
number and proportion of older adults [1]. An
ageing population increases the requirements
for health care systems, social services support
and changing family dynamics.
In 2017, two out of six deaths in the world
were from cancer, the second cause of death
after cardiovascular disease. Of these deaths,
almost half (46%) were in patients over 70 years
of age [2]. This is likely a consequence of three
main factors: (1) as the population increases, so
does the annual number of deaths, (2) the world
is getting wealthier and fewer people die pre-
maturely [3], and (3) cancer is a disease of age-
ing: as the global population ages, the incidence
and prevalence of cancer increases.
There is a lack of representation of older
adults and other vulnerable populations in
clinical trials across all areas of medicine [4],
including in the oncology setting [5, 6]; only
around 25% of cancer trials have enrolled par-
ticipants aged C 65 years [7]. This has huge
implications for treatment of older adults with
cancer. Firstly, there is a lack of good clinical
evidence in the older age group for health care
professionals and patients to make informed
treatment decisions. Medical bodies such as the
National Institutes for Health in the USA and
the National Institute for Health and Care
Excellence in the UK base treatment guidelines
and recommendations on trials primarily of
younger adults with cancer. As a result, the
medical community is providing cancer care to
older adults based on evidence that was
acquired in a different population: evidence
typically from patients with fewer comorbidi-
ties, less polypharmacy, better overall health
and different physiology [8].
A summary of the challenges discussed in
this article and potential solutions is given in
Table 1.
CHALLENGES
Reasons for the lack of inclusion in trials are
multifactorial and challenging. The main chal-
lenges in recruiting older adults to clinical trials
can be divided into three areas, which contain
some overlapping themes: (1) protocol factors
including recruitment and study design, (2)
patient factors including motivation and com-
peting comorbidities, and (3) sponsor factors
including motives of sponsors and relevant
funding agencies.
Protocol Factors
The literature suggests that older adults do want
to be involved in clinical trials [9] and find
inclusion a positive experience, even in studies
with a negative or neutral outcome [10]. How-
ever, they do not actively seek out trials they
can participate in [11]. Therefore, strategies for
recruitment to studies and trial design should
be specifically tailored to older adults.
Recruitment
The number of older patients who need to be
approached to recruit significant numbers to a
trial is much greater than their younger coun-
terparts [12]. In a review of 14 published ran-
domised controlled trials in various specialties
in older adults by McMurdo et al. [12], the
authors found that the number needed to
screen to recruit one older participant was
three, due to patient refusal to participate, for
various reasons, increasing the burden of work
on trialists.
There is inherent bias on the part of the
clinician and recruiting health care team in the
selection of patients for a clinical trial. A retro-
spective case-controlled study of patients with
breast cancer by Kemeny et al. [13] sought to
determine whether older patients were as likely
as younger patients to be offered and to accept
treatment in a clinical trial. The study
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demonstrated that older patients were signifi-
cantly less likely to be offered a clinical trial
(35% versus 51%, p = 0.006), however, if
offered, they were as likely as their younger
counterparts to accept enrolment. This suggests
that unconscious ageism is present within the
health care team.
An anonymous survey of approximately
1000 members of the Alliance for Clinical Trials
in Oncology group surveyed the opinion of
health care professionals, patient advocates and
research staff. Overall, one third felt that[ 50%
of clinical trials enrolees should be aged 65 or
above, and 64.8% felt that there was






Older adults do want to be included in trials, but are
less likely to be asked to participate
Different forms of communication and advertisement
may be required
Study design
In non-blinded trials, clinician bias towards a particular
treatment arm may result in non-inclusion of specific
patients
Older patients may have a pre-existing preference to
undergo or avoid certain therapies, even if survival is
impacted
Recruitment
Older adults may require additional support, and
appropriate time and resources should be allocated
here
Study design
Alternative study designs such as prospective cohort
studies or retrospective evaluations should be
considered
Endpoints of a trial should be modified to meet the




Maintaining quality of life may be more important
than prolonging survival
Positive relationships between study staff and
participants are important
Competing comorbidity
Physical obstacles which impede participation in a trial
include mobility issues, communication difficulty,
economic constraints and frailty
Patients with cognitive impairment are usually
excluded from clinical trials
Motivation
Trial funding should include consideration of
transportation of participants, additional
communication needs and supportive services
Competing comorbidity
Integration of geriatric assessment as routine in
cancer clinical trials
Standard protocols for inclusion of older adults with




There is under-representation of older adults in trials
by regulatory bodies
Inappropriate age limits and exclusion of frail patients
No penalty to sponsors for not including older adults
Ban on upper age limit for inclusion in clinical trials
Penalty for not providing information on number of
older adults recruited
Pressure on sponsors to raise awareness of these issues
Oncol Ther
improvement to be made in the enrolment of
older patients [14].
Methods of recruitment to clinical trials may
need to be tailored to older adults to overcome
barriers including communication deficits,
negative perceptions of potential trial partici-
pants and additional concerns from older adults
[15]. Harris et al. [16] compared methods of
recruitment by telephone or questionnaire to a
physical activity study in 560 older adults.
Telephone contact increased recruitment to the
study by 10% (95% CI 0.2–19.8%), but inclu-
sion of a questionnaire did not. Telephone
contact may have given the potential study
participants greater time and opportunity to
speak to a research nurse and receive further
information about the study if required. This
should be considered when designing a study;
more time and resources may need to be allo-
cated to provide this service.
Study Design
Increasing access for older adults to trials may
be hindered by trial design. For example, ran-
domised controlled trials of treatment versus
non-treatment or comparing two different
treatments, where the treatment(s) has poten-
tial side effects, with little patient benefit, such
as chemotherapy, may be less attractive to older
adults where maintenance of quality of life may
outweigh curative intent [17].
Using breast cancer as an example, there are
a number of notable trials in older women that
have failed to recruit significant numbers for
reasons related to both trial design and patient
factors. The Endocrine ± Surgical Therapy for
Elderly women with Mammary cancer
(ESTEeM) trial randomised women C 75 years
of age with invasive, operable, moderate or
strongly oestrogen receptor (ER)-positive breast
cancer to receive primary endocrine therapy
(PET) or surgery and adjuvant endocrine ther-
apy for 5 years [18]. The trial aimed to recruit
1200 patients; however, recruitment was extre-
mely slow, and the study only managed to
randomise nine patients and therefore closed
early.
The Adjuvant Cytotoxic Chemotherapy in
Older women (ACTION) trial randomised
women C 70 years of age with primary breast
cancer treated by surgery, who were defined as
high-risk of recurrence and had tumours which
were ER-negative or weakly positive, to receive
adjuvant chemotherapy or no further treatment
[19]. The initial phase of the trial aimed to
recruit 200 patients to evaluate the accrual rate
and tolerance of chemotherapy. Unfortunately,
recruitment was low and the trial was closed
early.
Although both studies address important
questions in this patient population, they were
difficult to conduct as randomised trials due to
the major differences in treatment arms, i.e.
surgery or PET in the ESTEeM trial and
chemotherapy or no chemotherapy in the
ACTION trial, as it was not possible to blind the
treatment options. This can cause bias in that
the clinician may have a preference towards one
treatment arm for a particular patient. Further-
more, invited patients may have had a pre-ex-
isting preference to undergo or avoid certain
therapies from the outset [20] and may be
averse to a particular treatment, even if it could
improve their survival [21].
Therefore, it could be suggested that ran-
domised controlled trials are not the preferable
method of choice to answer the hypothesis of
these studies in the older population. Alterna-
tive options, such as prospective cohort studies
or retrospective evaluation of national popula-
tion-based data sets, may answer questions
regarding oncological outcomes based on what
treatment the patient received [22].
Patient Factors
There are a number of patient-related factors to
consider for older adults who are approached to
be included in a clinical trial, including patient
motivation for inclusion and treatment goals, as
well as competing comorbidities, frailty and
how this might impact on physical
participation.
Motivation
As demonstrated by the ESTEeM and ACTION
trials, older adults may be less inclined to par-
ticipate in clinical trials which have a treatment
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arm with potential side effects which may
impact quality of life.
Moorcraft et al. [23] invited all patients who
had been approached about participation in
clinical trials at the gastrointestinal and lym-
phoma unit at their centre to complete a ques-
tionnaire about their experience. A total of 88%
of 276 patients were approached and consented
to participate in a clinical trial. Interestingly,
increased age (C 65 years) was not a factor as to
whether or not they would participate in a trial
(p = 0.236), nor was performance status
(p = 0.839). The most important reason for trial
participation irrespective of age was a belief that
‘the trial offered the best treatment available’ or
that ‘the trial results could benefit others’.
Interestingly, patients were more likely to state
that their main reason for participation was ‘the
trial results could benefit others’ if they
were\65 years of age compared to C 65 years
(64% versus 39%). This is important to consider
when approaching an older adult to participate
in a trial; maintenance of their own quality of
life may be the most important factor to them
when considering treatment.
When investigating why older adults partic-
ipated in a randomised trial of vascular disease
prevention, Tolmie et al. [24] found that
curiosity, self-interest and altruism were
important motivators. Study subjects were
likely to continue in the trial if positive rela-
tionships were formed between study staff and
participants, and if participants were kept
informed of the progress of the study at regular
intervals. This is an important point to note in
cancer trials, which may involve treatments
with more severe side effects, such as
chemotherapy.
Although there is limited evidence to estab-
lish why older adults participate in clinical tri-
als, particularly trials related to cancer, the take-
home message is that older adults do participate
in clinical trials when asked, although their
motives for doing so may be different compared
to their younger counterparts.
Competing Comorbidities
Greater likelihood of comorbidity in older
adults increases concerns of side effects from
additional treatments as well as placing physical
and psychological burdens on an older adult.
Typically, older people face a combination of
obstacles including comorbidity, economic
constraints, communication issues and physical
immobility that constrains transportation
options [7, 25]. They may have additional
accessibility needs such as help with reading
study material due to deterioration in eyesight
or help with understanding study instructions
due to hearing loss.
A huge issue arises concerning older patients
with cognitive impairment being automatically
excluded from clinical trials due to issues
regarding consent. This is particularly concern-
ing, as fewer patients with dementia present
with cancer at an early stage and are less likely
to have surgery versus non-surgical treatment
options [26]. There is an increasing global bur-
den of dementia; 40–50 million people are
currently living with dementia [27], and this is
predicted to double every 20 years [28]. There-
fore, cognitive impairment in a patient should
be treated as any other comorbidity affecting
the older population [29], and adjustments
should be made to allow these patients to par-
ticipate in clinical trials. Specifically when
considering patients with a diagnosis of
dementia, the stage of their disease journey is
important. Dementia is a disease with a very
long course; patients with milder disease earlier
in the course are still likely to retain decision-
making ability and should be offered trial
inclusion.
Sponsor Factors
Under-representation of older adults in trials by
regulatory agencies such as the National Insti-
tute for Health Research in the UK and the Food
and Drug Administration (FDA) in the USA has
been shown [30]. Conscious ageism occurs in
study design with inappropriate age limits and
exclusion of frail older patients [25]. Bayer and
Tadd [31] examined studies submitted to a local
research ethics committee and found that 20
out of 46 approved studies had an upper age
limit that seemed unjustifiable.
Lewis et al. [32] retrospectively analysed
clinical trials sponsored by the National Cancer
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Institute (NCI) in the USA, accounting for over
59,000 patients from 1997 to 2000. They found
that only 32% of participants were older adults,
compared with 61% of patients with incident
cancers. More recent data from the NCI (period
2001–2011) did not show any improvement in
this area [33].
In addition, Hernandez-Torres et al. [34]
looked at whether accrual of older adults to
trials led by the Canadian Cancer Trials Group
had increased from 2003 to the present time
and whether exclusion criteria had broadened.
Although there was a small increase in inclu-
sion, older adults remained under-represented.
Sponsors and regulatory agencies may be
more interested in the younger population, as
publicity from successful results is often more
pronounced in this cohort. Younger partici-
pants are less likely to have comorbidities that
could place them at higher risk for adverse
outcomes. Currently, there is no penalty for
exclusion and therefore no incentive for spon-
sors to promote the inclusion of older adults.
POTENTIAL SOLUTIONS
Many organisations including the American
Society of Clinical Oncology, the International
Society of Geriatric Oncology (SIOG) and the
European Organisation for Research and Treat-
ment of Cancer have issued recommendations
on strengthening the evidence base for treating
older patients with cancer by increasing their




It is accepted by older adults and health care
professionals that different methods of recruit-
ment to clinical trials is required to engage older
adults [12]; however, the type of additional
support and how this should be delivered
remains uncertain.
Greater support for older patients, for
example, follow-up telephone consultations to
check for understanding of patient information
sheets, has been found to be helpful [36], as well
as additional research staff available in clinics to
explain potential trials to patients and provide
educational materials to the patient and health
care team regarding potential treatment toxicity
[37]. However, other methods, such as receipt of
educational materials and financial incentives,
have not been found to be helpful. Kimmick
et al. [38] conducted a randomised trial com-
paring educational intervention with standard
information to improve accrual of cancer
patients aged C 65 years to group-sponsored
treatment trials. Educational intervention con-
sisted of an educational seminar, educational
materials, email reminder and a case discussion
seminar. Accrual of older patients was not
increased by this particular intervention.
The Medicare programme in the USA con-
ducted a longitudinal analysis of the enrolment
of older patients in NCI-sponsored cancer trials
from 1996–2003 [39]. The study compared
recruitment of older women to trials before and
after a reimbursement policy change was
introduced. The policy change extended reim-
bursement to cover participants of clinical tri-
als. The study found that a change in
reimbursement policy was not associated with
increased enrolment of older patients in cancer
trials.
Flexibility in the method of recruitment is
paramount, and investigators should not be
discouraged by a seeming lack of participation;
alternative methods should be planned from
the outset.
Study Design
The traditional design of randomised controlled
trials may not be the most appropriate design
for older adults, and there are a number of
potential alternative designs to consider [40].
Potential alternatives include prospective
cohort studies, the use of national population-
based data sets, or randomised trials with loose
inclusion/exclusion criteria, including prag-
matic trials. In response to the lack of success in
randomised controlled trials assessing adjuvant
chemotherapy in older women with breast
cancer, alternative study designs have been
sought.
Gray et al. [41] conducted a retrospective
cohort study in patients aged C 70 years with
Oncol Ther
early breast cancer, with and without high-level
comorbidity, identified from the Scottish Can-
cer Registry, with data linked to other health
records. They were able to identify 9653
patients with low comorbidity and 7965 with
high comorbidity. Propensity score matching
was used to estimate the effect of chemotherapy
on breast cancer mortality and overall survival,
adjusting for differences in prognosis between
those who received chemotherapy and those
who did not. The average predicted benefit of
chemotherapy was an additional three out of
every 100 women surviving for 10 years, and an
additional four out of every 100 for those with
comorbidity. The authors concluded that the
relative effectiveness of adjuvant chemotherapy
in older women appears similar to that in
younger women (recruited to clinical trials),
and this would imply that estimates of treat-
ment effectiveness among trial-eligible patients
are generalisable to trial-under-represented
groups.
A prospective cohort study was the approach
taken by Fietz et al. [42] in Germany. The team
recruited 2316 breast cancer patients, including
478 C 70 years, to a prospective registry which
included detailed patient and tumour charac-
teristics, treatment details and oncological out-
come. The proportion of patients receiving
taxane-based adjuvant chemotherapy was sim-
ilar independent of age (61% in the younger
cohort versus 62% in the older cohort). How-
ever, older patients with hormone receptor
positive tumours were more likely to receive
adjuvant endocrine therapy alone. Amongst the
patients who did receive adjuvant chemother-
apy, disease free survival was comparable
between younger and older patients (86% ver-
sus 88% at 3 years).
Randomised controlled trials with some ele-
ment of blinding may still be possible in older
adults, for example single-blinding of the
interventionist to allocation or control arm,
where older participants are not blinded to the
treatment, may encourage their participation
[43].
Endpoints of a trial should potentially be
modified in older adults. For example, instead
of overall survival or progression-free survival,
investigators might consider quality of life,
toxicity of treatment and maintaining func-
tional independence as markers of treatment
outcome in older adults. Measurement of dis-
ease-specific survival is useful as it indicates the
number of patients who actually die as a result
of cancer as opposed to other chronic condi-
tions [44].
Involvement of older adults through patient
and public involvement schemes, in order to
identify the most appropriate trial design, is
paramount.
Decentralised Clinical Trials
In recent times, there has been a dramatic
increase in the use of technology to help reduce
the burden placed on participants in clinical
trials. The urgent need for increased technology
know-how and user ability has been dramati-
cally highlighted by the current coronavirus
pandemic.
The term ‘decentralised clinical trials’ is used
to define those executed through telemedicine
and mobile or local health care providers, using
processes and technologies that differ from the
traditional clinical trial model [45]. Examples
include the use of telemedicine, teleconsent,
wearable devices and smartphone applications
for educational material, reminders and collec-
tion of patient-reported outcomes [46].
In order to ensure fluidity of the process,
there are a number of issues of basic technology
that must be overcome, including enabling a
secure and reliable telephone/video contact, as
well as financial reimbursement and legal and
regulatory issues [46].
Some examples specific to older adults in
cancer clinical trials include the use of elec-
tronic signature to avoid unnecessary hospital
visits for consenting, virtual screening assess-
ment to determine eligibility for investigation
and treatment, and routine follow-up appoint-
ments [47].
The rapid expansion and understanding of
how technology can be integrated into health
services in 2020 is exciting and, in addition to
current face-to-face services, can only improve




Older patients do not view age as an important
reason for refusing clinical trials [48]. Therefore,
we must consider how we can make participa-
tion in clinical trials easier for them. Trial
information should be provided in age-appro-
priate formats, which may include large-print
information leaflets and additional audio-visual
material for the hearing- and vision-impaired
[7]. When applying for trial funding, funds
should be considered to facilitate access to
supportive services for older adults, for exam-
ple, a research nurse trained in geriatrics, addi-
tional funding for transportation, and access to
information regarding social services and
support.
Competing Comorbidity
The FDA guidance ‘Cancer Clinical Trial Eligi-
bility Criteria: Patients with Organ Dysfunction
or Prior or Concurrent Malignancies’, published
in July 2020, clearly states that comorbidity
should not be a reason to automatically exclude
a person from a clinical trial, and provides
practical advice related to types of comorbidity
including renal, cardiac and hepatic problems
[49].
This can be achieved by inclusion of geriatric
assessment (GA) in clinical trials and robust
guidance for inclusion of patients with cogni-
tive impairment.
Geriatric assessment is recommended by
SIOG to be integrated into geriatric oncology,
but how it should be implemented and the
results acted upon remains less clear [50]. In a
clinical trial setting, there are two potential uses
for GA. Firstly, trials which involve different
treatment allocations should embed some form
of GA into their design so that patients can be
allocated to a particular trial arm or treated
specifically according to their needs as identi-
fied by GA, rather than simply being excluded
from a trial because they are too frail. Secondly,
all trials involving older adults should include
some form of GA in their protocol, to identify
specific needs of this population that can be
addressed to improve their overall quality of
life, general health and potentially the ability to
continue participating in the trial.
An example of a randomised trial designed
specifically for older patients that used geriatric
assessment tools is the Cancer and Leukemia
Group B (CALGB) 49907 trial [51], which com-
pared two different types of adjuvant
chemotherapy in older women with breast
cancer and nested within the trial a detailed
quality-of-life study [52]. Geriatric assessment
tools were integrated into the study to provide
insights on the quality of life of study partici-
pants while also addressing issues detected.
There are some geriatric assessment-based
tools, such as the Cancer and Ageing Research
Group (CARG) chemotherapy risk score [53]
and the Chemotherapy Risk Assessment Scale
for High-Age Patients (CRASH) [54], that have
been shown to be superior to standard measures
for predicting chemotherapy toxicity in older
adults. These tools would be useful additions to
any clinical trial protocol involving prescription
of chemotherapy.
Inclusion of older adults with dementia
requires support from a patient’s family and
care network, health care professionals, and
societies and organisations involved in the care
of older adults with dementia.
A number of resources have been designed to
help include older adults with dementia in
clinical trials. The National Institute on Aging
Imbedded Pragmatic Alzheimer’s Disease (AD)
and AD-Related Dementias Clinical Trials
(IMPACT) Collaboratory has convened a Design
and Statistics Core [55], the goals of which are
to support the design and conduct of embedded
pragmatic clinical trials in older adults with
dementia. The roles of this body include edu-
cation of scientists and health care providers in
trial design, production of literature to address
relevant challenges, designing potential inter-
ventions to tackle the challenges of multiple
comorbidities, and the incorporation of multi-
ple health care systems and stakeholders [56].
The Alzheimer’s Association has developed a
three-item questionnaire that can be integrated
into the informed consent process to assess
whether patients with Alzheimer’s disease do
have the capacity to make informed decisions
regarding participation in treatment [57]. This
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tool is designed to be quick and simple to
administer and could be incorporated into
routine clinical practice and trial recruitment.
Some studies have included proxy consent as
acceptable in their inclusion criteria. In the UK
Bridging the Age Gap in Breast Cancer study of
3375 older women, patients without cognitive
capacity were eligible to participate if a relative
or friend was willing to sign proxy consent [58].
With increased awareness of the importance
of recruiting older adults with cognitive
impairment and potential solutions, health care
professionals and scientists are more likely to
include defined protocols in their study
proposals.
Sponsor Factors
The FDA have released guidance regarding the
inclusion of older adults in trials. Their Guid-
ance for Industry [59, 60] encourages the fair
representation of older adults in clinical trials,
emphasising the importance of considering
common conditions related to ageing and
guidelines for geriatric labelling on drugs.
Although the guidelines do not require manu-
facturers to include sufficient numbers of older
adults in clinical trials, they encourage infor-
mation on the package insert regarding the
number of older adults recruited, thus raising
awareness of the issue [59, 60]. The FDA have
more recently made renewed efforts to promote
inclusion of older adults in clinical trials, by
promoting the establishment of partnerships to
provide travel assistance, updated guidance on
payment and reimbursement of research par-
ticipants [61], and discouraging upper age limits
for trials [62].
Further efforts should be made towards
improvements in this area, including a ban on
upper age limits for inclusion in clinical trials
and standardised protocols for sponsors to use
to allow routine inclusion of patients with
cognitive impairment. The American Society of
Clinical Oncology are in support of overarching
bodies to exert authority in this way; they have
developed recommendations which include
leverage on research designs and infrastructure
for trials involving older adults and increasing
the authority of the FDA to incentivise and
require research involving older adults with
cancer [30].
CONCLUSIONS
This article has outlined the challenges and
solutions to consider in the recruitment of older
adults to cancer clinical trials. Health care pro-
viders should be aware that a variety of methods
may be required to recruit greater numbers of
older adults, including additional staff and time
spent on going through trial details, follow-up
telephone calls and accessible information.
When designing studies for older adults with
cancer, trialists should be flexible in inclusion
criteria, study design and endpoints. Patients
with cognitive impairment should not be
excluded from participation in trials, and con-
sent from family or carers should be considered
as routine. Geriatric assessment in some form
should be embedded as standard in clinical tri-
als of older adults with cancer. There needs to
be increased pressure on sponsors to make the
inclusion of older adults in clinical trials
mandatory and to make the numbers recruited
available in the public domain. There is an
urgent need to address these issues on a global
scale. Moving forward, one option is for a geri-
atrician to work alongside an oncologist in the
context of research for older adults, similar to
what is being implemented in clinical service
delivery. Most importantly, older patients and
their carers should be considered key stake-
holders in clinical trials and actively involved in
all stages of the trial process from inception.
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42. Fietz T, Zahn M-O, Köhler A, Engel E, Frank M,
Kruggel L, et al. Routine treatment and outcome of
breast cancer in younger versus elderly patients:
results from the SENORA project of the prospective
German TMK cohort study. Breast Cancer Res Treat.
2018;167(2):567–78.
43. Allore HG, Tinettia ME, Gill TM, Peduzzi PN.
Experimental designs for multicomponent inter-
ventions among persons with multifactorial geri-
atric syndromes. Clinical Trials. 2005;2(1):13–21.
44. Whelehan S, Lynch O, Treacy N, Gleeson C, Oates
A, O’Donovan A. Optimising clinical trial design in
older cancer patients. Geriatrics (Basel, Switzer-
land). 2018;3(3):34.
45. Clinical Trials Transformation Initiative (CTTI).




46. Saini KS, de Las HB, Plummer R, Moreno V, Romano
M, de Castro J, et al. Reimagining global oncology
clinical trials for the postpandemic era: a call to
arms. JCO Glob Oncol. 2020;6:1357–62.
47. Doherty GJ, Goksu M, de Paula BHR. Rethinking
cancer clinical trials for COVID-19 and beyond. Nat
Cancer. 2020;1:568–72.
48. Townsley CA, Selby R, Siu LL. Systematic review of
barriers to the recruitment of older patients with
cancer onto clinical trials. J Clin Oncol.
2005;23(13):3112–24.
49. U.S. Department of Health and Human Services.
Food and Drug Administration. Cancer Clinical
Trial Eligibility Criteria: Patients with Organ Dys-
function or Prior or Concurrent Malignancies:
Guidance for Industry. 2020. https://www.fda.gov/
media/123745/download. Accessed 18 Jan 2020.
50. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl
S, Kunkler I, et al. Management of elderly patients
with breast cancer: updated recommendations of
the International Society of Geriatric Oncology
(SIOG) and European Society of Breast Cancer Spe-
cialists (EUSOMA). Lancet Oncol. 2012;13(4):
e148–60.
51. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB,
Budman D, et al. Adjuvant chemotherapy in older
and younger women with lymph node-positive
breast cancer. JAMA. 2005;293(9):1073–81.
52. Cohen HJ, Muss HB. The Cancer and Leukemia
Group B Cancer in the Elderly Committee:
addressing a major cancer need. Clin Cancer Res.
2006;12(11):3606s.
53. Hurria A, Mohile S, Gajra A, Klepin H, Muss H,
Chapman A, et al. Validation of a Prediction Tool
for Chemotherapy Toxicity in Older Adults With
Cancer. J Clin Oncol. 2016;34(20):2366–71.
54. Extermann M, Boler I, Reich RR, Lyman GH, Brown
RH, DeFelice J, et al. Predicting the risk of
chemotherapy toxicity in older patients: the Che-
motherapy Risk Assessment Scale for High-Age
Patients (CRASH) score. Cancer. 2012;118(13):
3377–86.
55. Mitchell SL, Mor V, Harrison J, McCarthy EP.
Embedded pragmatic trials in dementia care: real-
izing the vision of the NIA IMPACT Collaboratory.
J Am Geriatr Soc. 2020;68(Suppl 2):S1-s7.
56. Allore HG, Goldfeld KS, Gutman R, Li F, Monin JK,
Taljaard M, et al. Statistical considerations for
embedded pragmatic clinical trials in people living
with dementia. J Am Geriatr Soc. 2020;68(Suppl 2):
S68–73.
Oncol Ther
57. Palmer BW, Dunn LB, Appelbaum PS, Mudaliar S,
Thal L, Henry R, et al. Assessment of capacity to
consent to research among older persons with
schizophrenia, Alzheimer disease, or diabetes mel-
litus: comparison of a 3-item questionnaire with a
comprehensive standardized capacity instrument.
Arch Gen Psychiatry. 2005;62(7):726–33.
58. Morgan JL, George J, Holmes G, Martin C, Reed
MWR, Ward S, et al. Breast cancer surgery in older
women: outcomes of the Bridging Age Gap in
Breast Cancer study. Br J Surg. 2020;45:878.
59. US Food and Drug Administration Guidance for
Industry. Content and format for geriatric labeling.
2001. https://www.fda.gov/media/72141/
download. Accessed 14 Oct 2020.
60. Food and Drug Administration. Inclusion of Older
Adults in Cancer Clinical Trials: Guidance for
Industry (draft guidance). 2020. https://www.fda.
gov/media/135804/download. Accessed 18 Jan
2020.
61. US Food and Drug Administration. Payment and
Reimbursement to Research Subjects. 2018. https://
www.fda.gov/regulatory-information/search-fda-
guidance-documents/payment-and-
reimbursement-research-subjects. Accessed 14 Oct
2020.
62. US Food and Drug Administration. Good Review
Practice: Clinical Review of Investigational New
Drug Applications. 2013. https://www.fda.gov/
media/87621/download. Accessed 14 Oct 2020.
Oncol Ther
